Kiromic BioPharma Total Assets 2011-2026 | KRBP

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Kiromic BioPharma

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
8.54 M	12.2 M	12 M	30.7 M	12.8 K	2.65 M	876 K	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
30.7 M	12.8 K	9.56 M

Quarterly Total Assets Kiromic BioPharma

2024-Q3	2024-Q2	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
10.2 M	12.5 M	12.2 M	14.2 M	13.6 M	13.1 M	12 M	13 M	19.5 M	25.9 M	30.7 M	39 M	6.44 M	10.2 M	12.8 M	12.8 M	12.8 M	12.8 M	2.65 M	2.65 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
39 M	2.65 M	14.5 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
ACADIA Pharmaceuticals ACAD	1.19 B	$ 22.56	2.13 %	$ 3.74 B	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
argenx SE ARGX	8.68 B	$ 785.07	2.57 %	$ 25 B	Niderland
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	151 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Akebia Therapeutics AKBA	377 M	$ 1.43	3.62 %	$ 368 M	USA
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Allakos ALLK	244 M	-	-	$ 28.6 M	USA
Alnylam Pharmaceuticals ALNY	4.97 B	$ 327.25	2.42 %	$ 42.9 B	USA
AlloVir ALVR	122 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	107 M	-	-	$ 10.1 M	USA
Applied Therapeutics APLT	54.8 M	-	-	$ 8.42 M	USA
Alterity Therapeutics Limited ATHE	41.4 M	$ 3.9	3.7 %	$ 9.38 B	Australia
Autolus Therapeutics plc AUTL	589 M	$ 1.49	9.56 %	$ 397 M	Britain
AVROBIO AVRO	101 M	-	1083.1 %	$ 745 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Amphastar Pharmaceuticals AMPH	1.63 B	$ 20.4	-0.87 %	$ 954 M	USA
Aquestive Therapeutics AQST	160 M	$ 4.18	1.21 %	$ 447 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	124 M	$ 2.66	3.5 %	$ 16.7 M	USA
AstraZeneca PLC AZN	114 B	-	-	$ 96.9 B	Britain
Brainstorm Cell Therapeutics BCLI	1.02 M	-	-2.5 %	$ 5.88 M	USA
Arcutis Biotherapeutics ARQT	433 M	$ 24.61	5.76 %	$ 3.13 B	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
BeiGene, Ltd. BGNE	8.19 B	-	0.49 %	$ 251 B	Cayman-islands
Aeterna Zentaris AEZS	35.1 M	-	5.93 %	$ 314 M	Canada
Checkmate Pharmaceuticals CMPI	78.8 M	-	-	$ 231 M	USA
AgeX Therapeutics AGE	6.95 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
Cabaletta Bio CABA	165 M	$ 3.09	0.65 %	$ 310 M	USA
CymaBay Therapeutics CBAY	435 M	-	-	$ 3.45 B	USA
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
Codiak BioSciences CDAK	172 M	-	-55.98 %	$ 2.15 M	USA
Avid Bioservices CDMO	337 M	-	-	$ 789 M	USA
Cidara Therapeutics CDTX	215 M	-	-	$ 1.41 B	USA
AIkido Pharma AIKI	113 M	-	1.93 %	$ 17.4 M	USA
Aptose Biosciences APTO	10 M	-	-45.71 %	$ 1.2 M	Canada
Checkpoint Therapeutics CKPT	7.47 M	-	-	$ 169 M	USA
Celldex Therapeutics CLDX	583 M	$ 32.41	3.38 %	$ 2.15 B	USA
Celsion Corporation CLSN	12.3 M	-	-6.63 %	$ 13.9 M	USA
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
Chimerix CMRX	213 M	-	-	$ 756 M	USA
Concert Pharmaceuticals CNCE	165 M	-	-	$ 401 M	USA
Akari Therapeutics, Plc AKTX	47.9 M	$ 3.88	2.11 %	$ 261 B	Britain